(Q46735703)

English

The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

0 references

Robert F. Storey

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

Robert Buckland

1 reference

ORCID Public Data File 2021

author name string

Heather M Judge

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

Robert J Buckland

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

Atsuhiro Sugidachi

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

Joseph A Jakubowski

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

publication date

1 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

19

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

125-133

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

The platelet P2 receptors in arterial thrombosis.

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Central role of the P2Y12 receptor in platelet activation

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Clopidogrel resistance?

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

The difference between clopidogrel responsiveness and posttreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Monitoring of clopidogrel action: comparison of methods

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Microparticles in cardiovascular diseases.

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner.

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Platelet-neutrophil-interactions: linking hemostasis and inflammation

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

CD40 signaling and plaque instability

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets

1 reference

https://api.crossref.org/works/10.1080%2F09537100701694144

21 January 2018

Identifiers

10.1080/09537100701694144

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18297550

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46735703&oldid=2129065231"